

Adrenal Insufficiency Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes

DelveInsight's Adrenal Insufficiency Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, July 3, 2024 /EINPresswire.com/ -- DelveInsight's "Adrenal Insufficiency Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Adrenal Insufficiency, historical and forecasted epidemiology as well as the Adrenal Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



Adrenal Insufficiency Market

To Know in detail about the Adrenal Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Adrenal Insufficiency Market Forecast](#)

Some of the key facts of the Adrenal Insufficiency Market Report:

The Adrenal Insufficiency market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

According to the Adrenal Insufficiency organization, among one million people, 82-144 are diagnosed with primary adrenal insufficiency and 150-280 with secondary adrenal insufficiency. In children, genetic forms are more prevalent: congenital adrenal hyperplasia represents about 70% of cases, other genetic disorders about 6%, and autoimmune diseases account for only 10-15%.

Primary adrenal insufficiency (PAI) is rare, affecting 10-20 people per 100,000 population, with various causes. While tuberculosis remains a significant cause of PAI, Addison's disease and congenital adrenal hyperplasia (CAH) are now becoming more common. In industrialized countries, Addison's disease accounts for about 90% of non-CAH cases.

The epidemiology of adrenal insufficiency in children is not well-defined. Congenital adrenal hyperplasia (CAH) is the most common cause of primary adrenal insufficiency in children,

occurring in approximately one out of every 14,200 live births.

Key Adrenal Insufficiency Companies: Halozyme Therapeutics, Eton Pharmaceuticals, Diurnal Limited, SwanBio Therapeutics, Minoryx Therapeutics, Poxel SA, bluebird bio, and others

Key Adrenal Insufficiency Therapies: ATRS-1902, ZENEO Hydrocortisone Autoinjector, Infacort[®], Chronocort, SBT101, Leriglitazone, PXL065, Lenti-D, and others

The Adrenal Insufficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adrenal Insufficiency pipeline products will significantly revolutionize the Adrenal Insufficiency market dynamics.

Adrenal Insufficiency Overview

Adrenal insufficiency is a condition where the adrenal glands do not produce enough hormones, particularly cortisol and sometimes aldosterone. This can lead to symptoms like fatigue, muscle weakness, weight loss, low blood pressure, and abdominal pain. Causes include autoimmune disorders, infections, or damage to the adrenal glands. Treatment typically involves hormone replacement therapy.

Get a Free sample for the Adrenal Insufficiency Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/adrenal-insufficiency-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Adrenal Insufficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Adrenal Insufficiency Epidemiology Segmentation:

The Adrenal Insufficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Cases of Adrenal Insufficiency in the 7MM

Type-specific Cases of Adrenal Insufficiency in the 7MM

Type-specific Cases of Adrenal Insufficiency in the 7MM

Complication-specific Cases of Adrenal Insufficiency in the 7MM

Treatable Cases of Adrenal Insufficiency in the 7MM

Download the report to understand which factors are driving Adrenal Insufficiency epidemiology trends @ [Adrenal Insufficiency Epidemiology Forecast](#)

Adrenal Insufficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenal Insufficiency market or expected to get launched during the study period. The

analysis covers Adrenal Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Adrenal Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Adrenal Insufficiency Therapies and Key Companies

ATRS-1902: Halozyme Therapeutics

ZENEO Hydrocortisone Autoinjector: Eton Pharmaceuticals

Infacort®: Diurnal Limited

Chronocort: Diurnal Limited

SBT101: SwanBio Therapeutics, Inc.

Leriglitazone: Minoryx Therapeutics

PXL065: Poxel SA

Lenti-D: bluebird bio

Adrenal Insufficiency Market Strengths

There are reliable diagnostic tests available for identifying adrenal insufficiency, such as ACTH stimulation tests and cortisol level measurements.

There are many support groups like National Adrenal Diseases Foundation (NADF) (non-profit organization) which are dedicated to providing information, education, and support to patients diagnosed with adrenal diseases.

Adrenal Insufficiency Market Opportunities

Ongoing research can provide a better diagnostic approach and treatment in upcoming time.

Educating people about adrenal insufficiency may bring a great change in managing disease.

Scope of the Adrenal Insufficiency Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Adrenal Insufficiency Companies: Halozyme Therapeutics, Eton Pharmaceuticals, Diurnal Limited, SwanBio Therapeutics, Minoryx Therapeutics, Poxel SA, bluebird bio, and others

Key Adrenal Insufficiency Therapies: ATRS-1902, ZENEO Hydrocortisone Autoinjector, Infacort®, Chronocort, SBT101, Leriglitazone, PXL065, Lenti-D, and others

Adrenal Insufficiency Therapeutic Assessment: Adrenal Insufficiency current marketed and Adrenal Insufficiency emerging therapies

Adrenal Insufficiency Market Dynamics: Adrenal Insufficiency market drivers and Adrenal

Insufficiency market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Adrenal Insufficiency Unmet Needs, KOL's views, Analyst's views, Adrenal Insufficiency Market Access and Reimbursement

To know more about Adrenal Insufficiency companies working in the treatment market, visit @ [Adrenal Insufficiency Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Adrenal Insufficiency Market Report Introduction
2. Executive Summary for Adrenal Insufficiency
3. SWOT analysis of Adrenal Insufficiency
4. Adrenal Insufficiency Patient Share (%) Overview at a Glance
5. Adrenal Insufficiency Market Overview at a Glance
6. Adrenal Insufficiency Disease Background and Overview
7. Adrenal Insufficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Adrenal Insufficiency
9. Adrenal Insufficiency Current Treatment and Medical Practices
10. Adrenal Insufficiency Unmet Needs
11. Adrenal Insufficiency Emerging Therapies
12. Adrenal Insufficiency Market Outlook
13. Country-Wise Adrenal Insufficiency Market Analysis (2020–2034)
14. Adrenal Insufficiency Market Access and Reimbursement of Therapies
15. Adrenal Insufficiency Market Drivers
16. Adrenal Insufficiency Market Barriers
17. Adrenal Insufficiency Appendix
18. Adrenal Insufficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724947885>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.